Option chain shows key data for Alpha Cognition's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Alpha Cognition.

Alpha Cognition (NASDAQ:ACOG) Stock, Option Chain

Alpha Cognition

Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.

Brain,Degenerative,Diseases,Parkinson,,Alzheimer,,Puzzle

Analyst Color

News

Health Care

Initiation

Analyst Ratings

General

ACOG

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

Alpha Cognition Is &#39;Under-Followed&#39; As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst

Closeup,Of,Wall,St.,Street,Sign,And,Large,New,York

Markets

Trading Ideas

MLTX

This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Biotech

Contracts

Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer&#39;s Drug In China

Alpha Cognition Inc

Alpha Cognition Inc Ordinary Shares

Press Releases

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Alpha Cognition Announces Voluntary Delisting from CSE

Alpha Cognition Announces Partial Exercise of Over-allotment Option

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease

CSE:ACOG

HC Wainwright & Co.

Comments

Alpha Cognition

Alpha Cognition (ACOG) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga